1. Introduction {#sec1}
===============

1.1. Definition of a Positive Surgical Margin (PSM) in Radical Prostatectomy Specimens {#sec1.1}
--------------------------------------------------------------------------------------

As with all surgical specimens resected for cancer, the margins of a prostatectomy specimen are inked, usually using one color dye for the right side and one for the left. It is the pathologist\'s task to assess the microscopic slides and determine the proximity of tumor glands or cells to the ink to decide whether there is a definite positive surgical margin (PSM) ([Figure 1](#fig1){ref-type="fig"}).

A fundamental question is whether a tumor focus that is close to, but not touching, the resection margin ([Figure 2](#fig2){ref-type="fig"}) holds the same implications as a PSM. This question was first answered by Epstein and Sauvageot in 1997, in a study of 101 cases \[[@B1]\]. They found that patients with biochemical progression were no more likely to have tumor close to the margin than those without progression. Emerson et al., confining their study to just 278 margin-negative whole-mount prostate cases, validated that the closest distance between tumor and resection margin was not a significant predictor of PSA recurrence by univariate or multivariate analysis \[[@B2]\]. Thus, it was the consensus of the International Society of Urological Pathology in 2009 not to mention in written reports if tumor merely approaches but does not touch the margin \[[@B3]\]. This contrasts with the practice in other types of specimens such as breast lumpectomy specimens, in which the distance of tumor close to the margin is reported and does matter for outcome.

A PSM is a strong determinant of the probability of biochemical failure and is at least as important as grade, stage, and preoperative serum prostate-specific antigen (PSA). In unselected contemporary studies the PSM rate ranges from 8.8% \[[@B4]\] to 37% \[[@B5]\]. The interobserver reproducibility of designation of a PSM by urologic pathologists, using the definition of tumor on ink, has been shown to be good to excellent. The kappa value is 0.73 for definitive surgical margin status \[[@B6]\]. This supports the validity of many studies in concluding that, compared to negative surgical margin (NSM) status, a PSM correlates with a significant rise in biochemical failure rate. The purpose of this paper is to provide a compendium for urologists and their patients of all that is known about prostate margin status as an outcome predictor.

2. Methods {#sec2}
==========

A review of papers pertaining to prostate margin status and its effect on outcome was undertaken using PubMed searches from 1997 to the present.

3. Results {#sec3}
==========

3.1. Can Prostate Biopsy Results Predict Margin Status? {#sec3.1}
-------------------------------------------------------

We undertook a study a few years ago to determine the extent to which prostate biopsy results could predict cancer at prostatectomy that is unifocal, unilateral, margin-negative, and of small volume \[[@B7]\]. These four factors are the main criteria for choosing minimally invasive therapies such as targeted focal ablation of the prostate, as alternatives to radical prostatectomy. Unilateral cancer at prostatectomy was predicted by unilateral cancer in the biopsy (OR, 4.30) and unifocal cancer in the biopsy (OR, 2.63). In that study, negative surgical margins were predicted by unilateral cancer in the biopsy (OR 2.53, positive predictive value 82%). Therefore, biopsy findings can strongly predict prostatectomy margin status and other findings.

3.2. Comparison of PSM Rates by Technical Approach ([Table 1](#tab1){ref-type="table"}) {#sec3.2}
---------------------------------------------------------------------------------------

In the past decade, nonrobotic or robotic laparoscopic techniques have been increasingly used in place of conventional open radical prostatectomy. The laparoscopic approaches are often considered superior for continence and potency \[[@B8], [@B9], [@B11], [@B12], [@B10]\]. Most studies involving prostate pathology after laparoscopic approaches have found a PSM rate comparable with that of an open approach \[[@B13], [@B8], [@B12], [@B14], [@B15]\]. PSM rates were as follow: open, 7.6% \[[@B16]\] to 41.6% \[[@B17]\]; laparoscopic without robot, 11.3% \[[@B15]\] to 21.3% \[[@B8]\]; robotic, 13% \[[@B14]\] to 24.44% \[[@B17]\].

PSM rate for robotic approaches was found to be significantly worse than that for open ones (*P* = .007) in one study \[[@B16]\]; however, two other studies found open approaches superior to the robotic ones \[[@B18], [@B17]\]. In the study that found the open approach better, the result was confounded by nerve sparing, so robotic prostatectomies showed a nonsignificant trend toward lower PSM for a non-nerve-sparing approach (*P* = .09) \[[@B16]\]. When the anterograde open approach was compared with the retrograde approach, significantly fewer PSMs were found by retrograde approach (*P* = .03) \[[@B19]\].

In a comparison of robotic versus nonrobotic laparoscopic approaches, one study found the robotic method superior \[[@B8]\]. Another found that the outcome was highly stage dependent, with 7% of pT2 patients with biochemical failure as opposed to 34% of pT3 patients \[[@B9]\]. Failure could also depend on number of positive margins \[[@B10]\]. In a study evaluating the robotic approach, a lower PSM rate was achieved by cold incision of the dorsal venous complex before suture ligation \[[@B11]\].

3.3. Comparison of PSM Rates by Duration of Surgical Experience ([Table 2](#tab2){ref-type="table"}) {#sec3.3}
----------------------------------------------------------------------------------------------------

In the above comparison of surgical approaches, it must be noted that the new laparoscopic approaches have a demonstrable learning curve. That is, in three studies conducted in the middle of the 2000--2010 decade, the PSM rate improved after a few years of practice \[[@B20]--[@B22]\]. While a significant decrease in PSM rate occurred over time with a laparoscopic approach, PSM held steady for open procedures during the same time period \[[@B15]\]. Even with the open approach, during the 1990s and early 2000s, one study had noted that there was also a learning curve with respect to the PSM rate \[[@B23]\].

It is a bit disconcerting but it also must be admitted that individual surgeons may vary in their frequency of PSMs. In a study of 4,629 men operated on by open prostatectomy by one of 44 surgeons, for the 26 surgeons who each treated \>10 patients, the rate of PSM ranged from 10% to 48% \[[@B24]\]. A 6-fold difference was even reported for the same surgeon at different institutions \[[@B25]\].

3.4. Margin Status Effect on PSA Failure Rate at 10 Years ([Table 3](#tab3){ref-type="table"}) {#sec3.4}
----------------------------------------------------------------------------------------------

PSM rates in studies not comparing approaches ranged from 13% \[[@B26]\] to 42% \[[@B27]\] with a median 23% \[[@B28]\]. In the presence of a PSM, the failure rate was either double \[[@B30], [@B32], [@B35], [@B29], [@B31], [@B33], [@B34]\], triple \[[@B5], [@B36], [@B38], [@B37]\] or showed an increase of greater magnitude \[[@B4], [@B39]\] compared to NSM. Two studies did not specify this \[[@B5], [@B32]\]. In studies reporting a Hazard Ratio (HR) comparing a PSM to NSM, the HR ranged from 1.3 \[[@B40]\] up to 3.66 \[[@B33]\].

3.5. Tumor Stage ([Table 4](#tab4){ref-type="table"}) or Grade ([Table 5](#tab5){ref-type="table"}) Can Modify the Effect of PSM on PSA Failure Rates, at 10 Years {#sec3.5}
------------------------------------------------------------------------------------------------------------------------------------------------------------------

Nine studies compared PSA failure rates as a function of pathologic stage pT3a and pT3b versus pT2 or of pT3 versus pT2. (The apparent stage sometimes cannot be assessed because of capsular incision \[[@B41]\].) Failure rates with a PSM in stage pT2 ranged from 10.6% \[[@B37]\] to 63% \[[@B33]\], with an HR of 1.7 \[[@B4]\] to 3.81 \[[@B29]\] compared to having an NSM. For stage pT3a, failure rates were 38% \[[@B42]\] to 58% \[[@B43]\], with HR ranging from 1.4 \[[@B40]\] to 3.6 \[[@B4]\] compared to NSM. For stage pT3b, one study reports 71% failure, with HR of 1.4 compared to NSM \[[@B42]\]. Some studies chose to combine both pT3 substages and disclosed failure rates from 57% \[[@B44]\] to 75% \[[@B34]\] and HR of 4.1 \[[@B44]\] to 11.85 \[[@B37]\]. Thus, PSM exerts an effect that is synergistic with increasing stage, although the HR compared to NSM seems fairly constant across stages pT2, pT3a, and pT3b, at about 3 to 4. A study examining the phenomenon of capsular incision, sometimes denoted pT2+, found a 29.3% failure rate versus 7.3% for no incision (*P* \< .0001) \[[@B40]\].

The HR for failure with a PSM seems to increase with increasing Gleason score \[[@B4], [@B42], [@B33], [@B45]\]. In one study \[[@B29]\], however, after controlling for Gleason score, a PSM versus NSM with Gleason ≤7 was significantly predictive of failure, while PSM versus NSM with Gleason ≥8 was not (*P* = .115). Finally, Cao et al. noted that the Gleason score at the positive margin was predictive of biochemical recurrence \[[@B46]\]. Also, as the Gleason score of the main tumor rose, the concordance with the grade at the margin diminished: 99% for score 6 but 38% for score 9. By multivariate analysis, Gleason score at the margin predicted biochemical failure (*P* \< .05) \[[@B46]\].

3.6. The Effect of PSM on Mortality Rate at 10 Years Is Also Modified by Stage and Grade ([Table 6](#tab6){ref-type="table"}) {#sec3.6}
-----------------------------------------------------------------------------------------------------------------------------

Three studies addressed the prostate cancer-specific death rate in the presence of a PSM. Two studies, one based on the SEER cancer data registry \[[@B47]\], found a significantly higher death rate at 10 years in the presence of a PSM \[[@B29], [@B47]\], namely, 0.86% versus 0.33%  (*P* \< .001) and 2.6% versus 0.6% which was significant (*P* = .006). In another study, from the Mayo Clinic registry, a PSM was not a significant predictor of death among 11,729 cases (*P* = .15), but did predict death in the subset that was stage pT3 \[[@B29]\].

3.7. PSA Failure Rates after a PSM Are Influenced by Length and Number of PSM ([Table 7](#tab7){ref-type="table"}) and by Location of PSM ([Table 8](#tab8){ref-type="table"}) {#sec3.7}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Many pathologists report the length of a PSM. Using categorical PSM length cut-offs between 3 mm and 10 mm, length significantly affected outcome in many \[[@B43], [@B53], [@B50]--[@B52], [@B41]\] but not all \[[@B54]--[@B56]\] studies. Emerson et al. \[[@B57]\] found a PSM length \>3 mm to be a significant outcome predictor by univariate analysis but it fell short of significance by multivariate analysis (*P* = .076) \[[@B57]\]. Moreover, the length of PSM by frozen section predicted residual tumor in additionally resected neurovascular bundles by multivariate analysis (*P* \< .001) \[[@B59]\].

The number of PSMs probably lacks predictive value. In most studies, number of PSM was not significant for outcome \[[@B38], [@B27], [@B50], [@B52]\]. In two studies, multiple PSMs as opposed to a single PSM predicted failure (HR 1.4, *P* = .002 by multivariate analysis or HR = 2.19) \[[@B60], [@B41]\]. In another study, number of PSMs carried only borderline significance when ≥3 foci were positive compared to one (*P* = .06) and not significant for 2 foci compared to one \[[@B54]\]. Emerson et al. found that PSM number predicted failure by univariate analysis (*P* = .037) but lost most of its predictive value when adjusted for Gleason score (*P* = .076) \[[@B57]\].

The most common location of a PSM was in the posterior or posterolateral prostate \[[@B53], [@B50], [@B52]\], although one study found PSM equally common at the apex \[[@B23]\]. A positive apical soft tissue margin appears more consequential than a prostatic tissue margin \[[@B58]\]. Eastham et al. noted that the elevated risk of a posterior PSM means that "efforts to maintain adequate tissue covering including the routine excision of Denonvilliers\' fascia and a component of the fat of the anterior rectal wall should be made in all patients..." \[[@B23]\]. Broken down by various sites, a posterolateral PSM predicted failure in most studies \[[@B23], [@B51]\] but not all \[[@B52]\].

Comparing various sites of PSM, the effect of an apical PSM was not significantly different from PSM at posterolateral or other sites \[[@B38], [@B56], [@B41]\], and another study concluded that the PSM location seemed not to predict failure \[[@B57]\]. However, in two studies, a positive posterolateral margin predicted failure while the apical margin did not \[[@B23], [@B61]\]. Possibly, residual apical tumor is less viable than residual tumor in the posterolateral region.

4. Conclusion {#sec4}
=============

Prostate margin status is an important determinant of patient outcome after radical prostatectomy. In a 2010 College of American Pathologists survey, this feature was missing from 1% of pathology reports \[[@B62]\], thus the inclusion of this and other essential features is a quality assurance concern for pathologists. Most urologic pathologists endorse the reporting of the extensiveness of positive margins, expressed as length, number, or radial extent positive for tumor cells; all these measurements have some relevance toward outcome. The presence of a positive margin confers a 2-3-fold increased hazard ratio for biochemical recurrence---modified by stage and tumor grade---and necessitates close clinical followup.

![Prostatectomy specimen with a definite positive surgical margin (PSM). The inked resection margin transects tumor (400x).](PC2011-673021.001){#fig1}

![Prostatectomy specimen with negative surgical margin. Tumor approaches within less than 1 millimeter of the inked margin (400x).](PC2011-673021.002){#fig2}

###### 

Comparison of PSM rates by technical approach.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, yr   No. of pts   Cohort years   Median f/u, yr   Open                                         Laparoscopic       Robotic      Failure rate if PSM                                                                       
  ------------------ ------------ -------------- ---------------- -------------------------------------------- ------------------ ------------ ---------------------- ----------------------------- ------------------------------------ ------------------------------------------
  Williams\          4240         2004--2006                      20.1%                                                           17.4%                               17.4%                                                              
  2010 \[[@B13]\]                                                                                                                                                                                                                        

  Coelho\            ≥250^††^     1994--2009                      24.0%                                                           21.3%                               13.6%                                                              
  2010 \[[@B8]\]                                                                                                                                                                                                                         

  Sciarra\           200          2003--2007                      18% anterograde, 14% retrograde              *P* = .03          ---                                 ---                                                                ---
  2010 \[[@B19]\]                                                                                                                                                                                                                        

  Williams\          950          2005--2008                      7.6%                                                            13.5%,       HR 1.9\*, *P* = .007   ---                                                                ---
  2010 \[[@B16]\]                                                                                                                                                                                                                        

  Coelho\            876          2008-2009                       ---                                                             ---                                 pT2, 6.8%, pT3, 34.0%         *P* \< .0001                         ---
  2010 \[[@B9]\]                                                                                                                                                                                                                         

  Guru\              480          2005--2008                      ---                                                             ---                                 5% apical, 2% versus 8%\*\*                                        ---
  2009 \[[@B11]\]                                                                                                                                                                                                                        

  Bong\              301          1994--2006     2.0              24.7% at 1 institution but 4.2% at another   *P* \< .01\*\*\*   ---                                 ---                                                                25.6% at 1 institution but 100% at other
  2009 \[[@B25]\]                                                                                                                                                                                                                        

  Hakimi\            150          2001--2008                                                                                      13.7%                               12%                                                                6.7% versus 5.3%\
  2009 \[[@B12]\]                                                                                                                                                                                                                           *P* = .37

  Laurila\           192          2006                            14%                                                             ---                                 13%                           *P* = .5, no diff in apical margin   ---
  2009 \[[@B14]\]                                                                                                                                                                                                                        

  Terakawa\          137          2000--2007                      PSM                                          Not signif.        ---                                 More multiple PSM, get \#                                          ---
  2008 \[[@B10]\]                                                                                                                                                                                                                        

  Smith\             400          2002--2006                      35%^†^                                                          ---                                 15%                           *P* \< .001                          ---
  2007 \[[@B18]\]                                                                                                                                                                                                                        

  Silva\             179          1999--2003                      41.6%                                                           ---                                 24.44%                        *P* = .023                           ---
  2007 \[[@B17]\]                                                                                                                                                                                                                        

  Touijer\           1177         2003--2005                      11.0%;\                                                         11.3%;\      HR 1.2, *P* = .5       ---                                                                ---
  2007 \[[@B15]\]                                                 pT2 5.3%,\                                                      pT2 8.2%;\                                                                                             
                                                                  pT3 22.0%                                                       pT3 17.2%                                                                                              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*OR falls to 1.6 if nerve-sparing is eliminated as a variable (*P* = .05).

\*\*Lower rate achieved by cold incision of the dorsal venous complex before suture ligation.

\*\*\*For the same surgeon; but higher average pathologic stage at the first institution.

^†^But open method was used for more high-risk cases and also cases with a higher preoperative PSA, *P* = .002.

^††^Review of several papers.

###### 

Comparison of PSM rates by duration of surgical experience.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, yr            Number of cases            Cohort years                PSM rate                                                          
  --------------------------- -------------------------- --------------------------- ----------------------- ----------------------------------------- --------------------------------------------------------------------------
  Rodriguez 2010 \[[@B20]\]   400, by intervals of 100   2004--2006                  ---                     For pT2: 28.4%--31.9% to 11.6%--11.5%\*   ---

  Yee 2009 \[[@B21]\]         50, then 250               2005--2008                  ---                     ---                                       Cases  1--50: 36%,\
                                                                                                                                                       51--250: 17.6%,\
                                                                                                                                                       251--450: 7.5%

  Liss 2008 \[[@B22]\]        216                        2003--2007                  ---                     ---                                       14.8%, decr. over time *P* = .03, nerve-sparing increased risk *P* = .03

  Eastham 2007 \[[@B23]\]     2442                       1983--1990 and 1991--2004   18% versus 10%,\        ---                                       ---
                                                                                     *P* = .001                                                        

  Touijer 2007 \[[@B15]\]     1177                       2003--2005                  No decrease over time   Decreased over time, *P* = .0002          ---
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*First 200 cases versus last 200 cases.

###### 

The effect of margin status on PSA failure rate at 10 years.

  First author, yr               *n*       Cohort years   PSA fail criterion, ng/mL   \% PSM, overall   \% biochemical failure rate          
  ------------------------------ --------- -------------- --------------------------- ----------------- ----------------------------- ------ ------------------------------------
  Williams 2011 \[[@B26]\]       158^††^   2005--2009     ---                         13                No f/u                               
  Ahyai 2010 \[[@B36]\]          932       1992--2004     ≥0.1                        12.9              21.7                          6.9    *P* = .001
  Tsao 2009 \[[@B28]\]           100\*     2004--2007     ≥0.2                        23                ---                                  
  Sæther 2008 \[[@B30]\]         219       1996--2004     ≥0.2                        32.4              40                            18     *P* = .017
  Pfitzenmaier 2008 \[[@B38]\]   406       1990--2006     ≥0.2                        17.2              64.3                          20.5   *P* \< .001, HR 3.21
  Swanson 2007 \[[@B32]\]        719       1985--1995     ≥0.3                        15.3              63                            27     *P* \< .0001
  Ahyai 2010 \[[@B36]\]          936       1992--2003     ≥0.4                        37                19                            7      *P* \< .01
  Kausik 2002 \[[@B27]\]         1202^†^   1987--1995     \>0.2                       42                35                            24     *P* = .0001
  Menon 2010 \[[@B35]\]          1384      2001--2005\*   ≥0.2                        25.1              ---                           ---    *P* \< .0001, HR 2.43 (1.72--3.42)

\*Robotic only.

^†^pT3 cases only.

^††^pT2 cases only.

###### 

Modification of PSA failure rates according to stage, at 10 years (unless specified).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, yr                         *n*       Cohort Years   PSA fail criterion ng/mL   \% PSM, overall                            \% biochemical failure rate   \% biochemical failure rate with PSM by stage                                                                                                                                                               
  ---------------------------------------- --------- -------------- -------------------------- ------------------------------------------ ----------------------------- ----------------------------------------------- ------------------------- --------------------- ----------------------- ------------------------------------------ ------------------------ --------------- ----------------------
  Williams\                                4240      2004--2006     ---                        19.4                                       No f/u                                                                                                  14.9                                          42                                                                  ---             
  2010 \[[@B13]\]                                                                                                                                                                                                                                                                                                                                                                   

  Ploussard\                               1943      2000--2008     \>0.2                      25.6                                       54.2                          29.9                                            *P* \< .001, HR 2.6                             *P* \< .001, HR 3.81                                               *P* = .001, HR 2.09                      *P* = .1, HR 1.46
  2010 \[[@B29]\]                                                                                                                                                                                                                                                                                                                                                                   

  Budäus\                                  4490      1992--2008     ≥0.1                       18.9                                       ---                                                                                                     17 versus 5           HR 2.9                  38 versus 26                               HR 1.9                   71 versus 53,   HR 1.4
  2010 \[[@B42]\]                                                                                                                                                                                                                                                                                                                                                                   

  Brimo\                                   108^†^    1995--2008     ≥0.2                       Inclusion criterion^†^                     ---                                                                                                                           ---                     58                                                                  ---             
  2010 \[[@B43]\]                                                                                                                                                                                                                                                                                                                                                                   

  Hsu\                                     164       1977--2004     ≥0.2                       48.2\                                      ---                                                                                                                           ---                     57%, HR 4.1, *P* = .03                                                              
  2010 \[[@B44]\]                                                                              (all cT3)                                                                                                                                                                                                                                                                            

  Ficarra\                                 322\*     2005--2008     ≥0.2                       29.5                                       6.2                           1.8                                             *P* \< .001 (at 12 mo.)   10.6                                          57.5                                       *P* \< .001, HR = 11.8   72.2            
  2009 \[[@B37]\]                                                                                                                                                                                                                                                                                                                                                                   

  Kwak\                                    266       1995--2007     ≥0.2                       18.5                                       52.6                          8                                               *P* \< .0001              29.3 versus 7.3^\$^   *P* \< .0001            51 versus 10.5                             *P* = .04\               ---             
  2010 \[[@B39]\]                                                                                                                                                                                                                                                                                                                          HR 1.4,                                  

  Hashimoto\                               238\*\*   1985--2005     ≥0.2                       34.4                                       38.4                          19.3                                            *P* \< .001                                     HR = 1                                                             *P* = .033 HR 3.36,                      *P* = .002, HR 7.13,
  2008 \[[@B31]\]                                                                                                                                                                                                                                                                                                                                                                   

  Chuang\                                  135\*\*   1993--2004     ≥0.2                       ---                                        ---                                                                                                     28.7 versus 3.3       *P* \< .0001            Focal EPE 21.4% versus 10.3%, *P* = .02,                                            
  2007 \[[@B53]\]                                                                                                                                                                                                                                                                                                                                                                   

  Ext EPE 41.5% versus 26%, *P* \< .0001                                                                                                                                                                                                                                                                                                                                            

  Orvieto\                                 996       1994--2004     ≥0.1                       8.8 (all); pT2 1.7, pT3a 24.9, pT3b 27.1   35                            7.8                                             *P* \< .001, HR 3.27                            *P* \< .001, HR = 1.7                                              *P* = .011, HR 3.6                       *P* = .19, HR 6.5
  2006 \[[@B4]\]                                                                                                                                                                                                                                                                                                                                                                    

  Karakiewicz\                             5831      1983--2000     ≥0.1--≥0.4                 26.7                                       63.9                          29.9                                            *P* = .001, HR 3.66       63 versus 30          *P* \< .001             ---                                                                 ---             
  2005 \[[@B33]\]                                                                                                                                                                                                                                                                                                                                                                   

  Swindle\                                 1369      1983--2000     ≥0.4                       12.9 (all); pT2 6.8, pT3 23                42                            19                                              *P* = .002, HR 1.52       38.6 versus 19.6      *P* \< .001             74.9% versus 53.8%, *P* \< .001                                                     
  2005 \[[@B34]\]                                                                                                                                                                                                                                                                                                                                                                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Robotic only.

\*\*Study used 5-year biochemical recurrence.

^†^Restricted to GS = 7, stage pT3a, and PSM.

^\$^If there is capsular incision, versus no capsular incision.

###### 

Modification of PSA failure rates according to grade, at 10 years (unless specified).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, yr   *n*         Cohort years   PSA Fail criterion, ng/mL   \% PSM, overall                          \% biochemical failure rate   Gleason score effect on failure if PSM                                                                       
  ------------------ ----------- -------------- --------------------------- ---------------------------------------- ----------------------------- ---------------------------------------- --------------- --------------------------------------------------- ----------------------
  Ploussard\         1943        2000--2008     \>0.2                       25.6                                     54.2                          29.9                                     *P* \< .001\    ≤7 versus ≥8                                        *P* \< .001\
  2010 \[[@B29]\]                                                                                                                                                                           HR 2.6                                                              *P* = .115

  Budäus\            4490        1992--2008     ≥0.1                        18.9                                     ---                           ---                                                      compared to GS = 6: for 3 + 4, for 4 + 3, for ≥8,   HR 2.81\
  2010 \[[@B42]\]                                                                                                                                                                                                                                               HR 6.57 HR 9.86,\
                                                                                                                                                                                                                                                                all *P* \< .001

  Brimo\             108^†^      1995--2008     ≥0.2                        Inclusion criterion^†^                   ---                           ---                                                      Score at margin                                     *P* = .007
  2010 \[[@B43]\]                                                                                                                                                                                                                                               

  Alkhateeb\         11,729^‡^   1992--2008     ≥0.4                        31.1                                     56                            77                                       *P* \< .0001\   Low risk 5.1% versus 0.4%;\                         ---
  2010 \[[@B45]\]                                                                                                                                                                           HR 1.63         med. risk 17% versus 65%;\                          
                                                                                                                                                                                                            hi. risk 43.9% versus 21.5%                         

  Orvieto\           996         1994--2004     ≥0.1                        All 8.8; pT2 1.7, pT3a 24.9, pT3b 27.1   35                            7.8                                      *P* \< .001\    7 versus ≥8,                                        *P* \< .001, HR 7.2\
  2006 \[[@B4]\]                                                                                                                                                                            HR 3.27                                                             *P* \< .001, HR 21

  Karakiewicz\       5831        1983--2000     ≥0.1 to ≥0.4                26.7                                     63.9                          29.9                                     *P* = .001\     ≥7                                                  *P* ≤ .008, HR 2.81
  2005 \[[@B33]\]                                                                                                                                                                           HR 3.66                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^†^Restricted to GS = 7, stage pT3a, and PSM.

^‡^Risk groups based on Gleason score and preoperative PSA: low = PSA \<10, Gleason ≤6; medium = PSA 10--20 or Gleason 7; high = PSA \>20 or Gleason ≥8.

###### 

Modification of prostate cancer mortality rates according to stage or grade, at 10 years.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, yr            *n*      PSA Fail criterion, ng/mL   PSM, %   Median f/u, yr   PCa death rate if   PSM rate or HR by stage   PSM rate by grade                                                                 
  --------------------------- -------- --------------------------- -------- ---------------- ------------------- ------------------------- ---------------------------- -------- ---------------------- -------------------- -------------
  Wright\                     65,633   ---                         21.2     7                0.86                0.33                      *P* \< .001                  17.7%    43.8%, *P* \< .001     27.5% versus 18.3%   *P* \< .001
  2010 \[[@B47]\]                                                                                                                                                                                                            

  Boorjian 2010 \[[@B29]\]    11,729   ≥0.4                        31.1     8.2              4                   1                         *P* = .15                    HR 1.0   HR 2.1, *P* \< .0001   ---                  ---

  Ploussard 2010 \[[@B29]\]   1943     \>0.2                       25.6     6.7              2.6                 0.6                       *P* = .006, 3.7 (1.5--9.5)   16.0     33.6--40.2             ---                  ---
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Modification of PSA failure rates according to PSM length or number of PSM, at 10 years (unless specified).

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, yr   *n*         Cohort years   PSA fail criterion ng/mL   Median f/u, yr   PSM, overall          %Biochemical failure rate   According to length at margin   According to number of PSM                                                                                          
  ------------------ ----------- -------------- -------------------------- ---------------- --------------------- --------------------------- ------------------------------- ---------------------------- -------------------------- ---------------------------- ------------------------------ ----------------------------
  Brimo\             108^†^      1995--2008     ≥0.2                       3.0              Inclusion criterion   ---                         ---                                                          \>3 mm:\                   *P* = .004\                  ---                            ---
  2010 \[[@B43]\]                                                                                                                                                                                          as continuous variable     *P* = .015                                                  

  van Oort\          174\*       1995--2005     ≥0.1                       3.0              Inclusion criterion   29                          ---                                                          \>10 mm,\                  HR 2.3, *P* = .022           \>1 versus 1                   HR 1.46 *P* = .24
  2010 \[[@B50]\]                                                                                                                                                                                          39% versus 21%                                                                         

  Lake\              1997        1996--2008     \>0.2                      4.1              18, 6.7 for T2        ext. 62, focal 36           16%                             *P* \< .0001                 extensive 62%,\            *P* \< .0001                 ---                            ---
  2010 \[[@B51]\]                                                                                                                                                                                          focal 36%\                                                                             
                                                                                                                                                                                                           negative 16%                                                                           

  Stephenson\        7160        1995--2006     ≥0.2                       3.2              21                    40                                                          *P* \< .001, HR = 2.3        extensive 66%, focal 34%   HR 1.3, *P* = .004^†^        multiple 83%,\                 HR 1.4, MVA ^†^ *P* = .002
  2009 \[[@B40]\]                                                                                                                                                                                                                                                  one 17%                        

  Shikanov\          1398        2003--2008     ≥0.1                       1.0              17\*\*                ---                                                         *P* \< .0001, HR 4.4         \<1 mm 1--3 mm \>3 mm      HR 0.26\                     ?                              *P* = .3\
  2009 \[[@B52]\]                                                                                                                                                                                                                     HR 9.6,\                                                    for fail
                                                                                                                                                                                                                                      *P* = .03\                                                  
                                                                                                                                                                                                                                      HR 14.8,\                                                   
                                                                                                                                                                                                                                      *P* = .01                                                   

  Goetzl\            103         1998--2008     ≥0.2                       ---              23.3                  ---                         ---                                                          ≥6 mm                      HR 1.7, *P* = .10            ≥3 PSM versus 1 versus 2 PSM   HR 1.3, *P* = .06\
  2009 \[[@B54]\]                                                                                                                                                                                                                                                                                 Not sig.

  Pfitzenmaier\      406         1990--2006     ≥0.2                       5.2              17.2                  64.3                        20.5                            *P* \< .001,\                ---                        ---                          ≥3 versus 1                    *P* = .46
  2008 \[[@B38]\]                                                                                                                                                             HR 3.21                                                                                                             

  Marks\             158         1990--1998     ≥0.1                       4                ---                   55                          ---                                                          ≥5 mm                      HR 1.00, *P* = .26           ---                            ---
  2007 \[[@B55]\]                                                                                                                                                                                                                                                                                 

  Vis\               281         1994--1999     ≥0.1                       6.75             23.5                  33.3                        7.9                             *P* \< .005                  Focal versus extensive     *P* = .49                    ---                            ---
  2006 \[[@B56]\]                                                                                                                                                                                                                                                                                 

  Emerson\           369         1999--2003     ≥0.1                       1.0              23                    25.6                        ---                                                          Median 3 mm                *P* = .031 univariate but\   Mean 2.45 versus 1.80          *P* = .037\
  2005 \[[@B57]\]                                                                                                                                                                                                                     .076 multivar.^††^                                          by univar. analysis

  Sofer\             498                        ≥0.2                       4 yr 5 mo        19.7                                                                              HR 2.8, *P* \< .05                                                                   ≥2, versus 1                   *P* = NS
  2002 \[[@B60]\]                                                                                                                                                                                                                                                                                 

  Kausik\            1202^†††^   1987--1995     \>0.2                      4.9              42                    35                          24                              *P* = .0001                  ---                                                     ≥2,\                           *P* = NS
  2002 \[[@B27]\]                                                                                                                                                                                                                                                  62% versus 1, 65%              

  Fromont\           734         1992--1999     ≥0.2                                        25                    ---                                                                                      ---                                                     \>2 versus 1                   HR 2.19,\
  2004 \[[@B59]\]                                                                                                                                                                                                                                                                                 *P* not done
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Study used 5-year biochemical recurrence.

\*\*Robotic only.

^†^But a predictive model nomogram does not improve accuracy of predicting failure after prostatectomy.

^††^Linear extent of positivity was associated with other pathologic variables such as preoperative PSA and tumor volume and not independently predictive when adjusted for Gleason score.

^†††^pT3 cases only.

###### 

Location of PSM and their modification of PSA failure rates, at 10 years (unless specified).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, yr   *n*             Cohort years   PSA fail criterion, ng/mL   Medi-an f/u, yr   %PSM, overall                                              %Biochemical failure rate   Failure according to PSM location   Most common location                                                                                                                                      
  ------------------ --------------- -------------- --------------------------- ----------------- ---------------------------------------------------------- --------------------------- ----------------------------------- ----------------------------------- ------------------------------------------------------- ------------------------------------------------------------- ------------------------
  van Oort\          174\*\*\*       1995--2005     ≥0.1                        3.0               Inclusion criterion                                        29                                                                                                  ---                                                                                                                   Post 43%,\
  2010 \[[@B50]\]                                                                                                                                                                                                                                                                                                                                                                      ant 35%,\
                                                                                                                                                                                                                                                                                                                                                                                       apex 33%

  Lake\              1997            1996--2008     \>0.2                       4.1               18, 6.7 for T2                                             Ext. 62 focal 36            16                                  *P* \< .0001                        Apex\                                                   HR 2.24, *P* = .03, HR 3.7, *P* \< .0001 HR 2.5, *P* = .002   ---
  2010 \[[@B51]\]                                                                                                                                                                                                                                                Ant\                                                                                                                  
                                                                                                                                                                                                                                                                 Posterolat                                                                                                            

  Godoy\             246^∗∗,\ ∗∗∗^   2000--2006     \>0.15                      2.8               Apical surgical, 3.2, apical soft tissue, 6.6; total 9.8   ---                                                                                                 Apical surgical 48.6%, apical soft tissue, 4.7%\*\*\*                                                                 
  2009 \[[@B58]\]                                                                                                                                                                                                                                                                                                                                                                      

  Stephenson\        7160            1995--2006     ≥0.2                        3.2               21                                                         40                          HR = 2.3                            *P* \< .001                         Apex versus other                                       HR 1.1, *P* = .3                                              ---
  2009 \[[@B40]\]                                                                                                                                                                                                                                                                                                                                                                      

  Shikanov\          1398            2003--2008     ≥0.1                        1.0               17\*\*                                                     ---                         ---                                 *P* \< .0001 HR 4.4                 Posterolateral                                          *P* = .7 for fail                                             Posterolat 45%;\
  2009 \[[@B52]\]                                                                                                                                                                                                                                                                                                                                                                      apex 29%;\
                                                                                                                                                                                                                                                                                                                                                                                       base 6%

  Pfitzenmaier\      406             1990--2006     ≥0.2                        5.2               17.2                                                       64.3                        20.5                                *P* \< .001 HR 3.21                 Apex versus nonapex                                     *P* = .21                                                     
  2008 \[[@B38]\]                                                                                                                                                                                                                                                                                                                                                                      

  Eastham\           2442            1983--2004     ≥0.2                        2.9               11.2,\                                                     25                          10                                  *P* = .0005 HR 1.39                 Posterolat.\                                            HR 2.80 HR 1.96 versus neg, *P* \< .0005                      Apex 37%,\
  2007 \[[@B23]\]                                                                                 pT2 7,\                                                                                                                                                        Posterior                                                                                                             posterolat 35%
                                                                                                  pT3 22                                                                                                                                                                                                                                                                               

  Chuang\            135^†∗∗∗^       1993--2004     ≥0.2                        ---               ---                                                        28.7\*\*\*                  3.3                                 *P* \< .0001                                                                                                                                              posterolat 61.5%\
  2007 \[[@B53]\]                                                                                                                                                                                                                                                                                                                                                                      post 19%\
                                                                                                                                                                                                                                                                                                                                                                                       ant 9%

  Vis\               281             1994--1999     ≥0.1                        6.75              23.5                                                       33.3                        7.9                                 *P* \< .005                         Apex versus other                                       *P* = .65                                                     ---
  2006 \[[@B56]\]                                                                                                                                                                                                                                                                                                                                                                      

  Emerson\           369             1999--2003     ≥0.1                        1.0               23                                                         25.6                        ---                                                                     Location, gen\'l:Ass\'n for \# of lateral sites:        *P* = .437\                                                   
  2005 \[[@B57]\]                                                                                                                                                                                                                                                                                                        *P* = .06                                                     

  Pettus\            498                            ≥0.2                        4.4               19.7                                                                                                                       HR 2.9, *P* \< .05, See breakdown   apex 21% nonapex 26%                                    *P* = .25, HR 2.25, *P* \< .05, HR 2.96                       apex 5.6, nonapex 11.4
  2004 \[[@B61]\]                                                                                                                                                                                                                                                                                                                                                                      

  Kausik\            1202^††^        1987--1995     \>0.2                       4.9               42                                                         35                          24                                  *P* = .0001                         ---                                                                                                                   apex 46% post. 64%
  2002 \[[@B27]\]                                                                                                                                                                                                                                                                                                                                                                      

  Sofer\             734             1992--1999     ≥0.2                                          25                                                         ---                         ---                                 ---                                 ---                                                                                                                   apex 45%; post. 32%
  2002 \[[@B60]\]                                                                                                                                                                                                                                                                                                                                                                      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*\*Robotic only.

\*\*\*Study used 5-year biochemical recurrence.

^†^pT2 cases only.

^††^pT3 cases only.

[^1]: Academic Editor: R. Montironi
